UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorp ...

财务数据和关键指标变化 - 第一季度收入为24.5亿美元,同比下降5.5亿美元 [13] - 毛利率保持强劲,达到60.3% [34] - 经调整EBITDA为1.6亿美元,占收入的6.6% [35] - 经调整每股收益下降,主要是由于收入减少和毛利率下降 [38][39][40] 各条业务线数据和关键指标变化 - 美洲地区收入下降6.6%,主要是由于预临床产品需求减弱 [14] - 欧洲地区收入下降16%,受到紧缩的政府和制药公司预算影响 [16][17] - 中国和亚太地区收入下降35%,持续受到资本设备支出疲软的影响 [18] 公司战略和发展方向 - 公司重点加强基础业务,推出新产品如SoHo共享房笼遥测系统和Ponemah软件 [21][22][23][24] - 同时拓展生物制造和器官芽等高增长领域,推出相关产品和解决方案 [25][26][27][28][29] 管理层对经营环境和未来前景的评论 - 预计全年收入与2023年持平,上半年疲弱但下半年有望恢复增长 [47] - 预计毛利率维持在60%左右,经调整EBITDA率将提升至中高teens [48] - 中国市场在第二季度仍将疲弱,但有望在下半年随政府刺激政策而改善 [73] - 新产品推广和生物制造等新兴业务有望成为公司未来重要的增长动力 [53][54][55][56][57] 问答环节重要的提问和回答 问题1 **Paul Knight 提问** 电穿孔技术是否是2024年最大的增长驱动力,新产品在2024年收入中占比多少? [52] **Jim Green 回答** 电穿孔和生物制造约占10%收入,预计未来2-3年将贡献2-4个百分点的整体增长 [53][54][55][56][57] 问题2 **Bruce Jackson 提问** 二季度收入预期如何,中国市场何时能恢复? [66] **Jim Green 回答** 预计二季度会有一定程度的环比改善,中国市场有望在三四季度恢复增长 [68][69][70][71][72][73] 问题3 **Frank DiLorenzo 提问** 公司有何成本优化措施,以及对经常性收入的目标是什么? [79] **Jim Green 回答** 通过精简人员等措施实现约4000万美元的年度成本节约,同时将努力推动经常性收入占比达到10%以上 [84][85][86][87]

Harvard Bioscience (HBIO) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this medical instruments maker would post earnings of $0.05 per share when it actually produced earnings of $0.04, delivering a surprise of -20%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Harv ...

Exhibit 99.1 Harvard Bioscience Announces First Quarter 2024 Financial Results Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 7, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong ...

HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast sh ...

HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast sh ...

HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million. Jim Green, Harvard Bioscience Chairman and CEO, said, "We re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorpor ...

财务数据和关键指标变化 - 2023年第四季度收入为2820万美元,同比下降1%,但剔除汇率和停产产品影响后,核心收入同比增长约1个百分点 [4][5] - 毛利率为58%,同比提升230个基点 [7] - 经调整营业利润为330万美元,约占收入的11.6%,与去年持平 [5] - 经调整EBITDA为370万美元,约占收入的13%,与去年持平 [7] - 经调整每股收益为0.04美元,与去年持平 [5] - 经营活动产生的现金流为430万美元,去年同期为270万美元 [7] 各条业务线数据和关键指标变化 - 美洲地区收入增长4.1%,剔除停产产品影响后核心收入增长约6%,其中临床前系统的遥测和Ponemah企业软件表现强劲,但呼吸产品受到疫情后恢复的影响 [5] - 欧洲中东非洲地区收入增长3.1%,剔除汇率和停产产品影响后增长约2个百分点,临床前系统有温和增长,得益于大型CRO客户首次安装新的高容量VivaMARS行为系统 [5] - 中国及亚太地区收入下降15%,剔除汇率和停产产品影响后下降约10%,主要受到学术客户需求疲软的影响 [5] 公司战略和发展方向及行业竞争 - 公司将通过新产品推出来加强基础业务,包括新的SoHo共享房笼遥测系统和集成VivaMARS高容量行为测试系统的Ponemah软件平台 [5][6] - 公司正在拓展到高容量工业应用,VivaMARS高容量行为系统在第四季度获得首个CRO客户订单 [6] - 公司正在拓展到生物制造领域,推出了适用于生物制造质量控制的氨基酸分析仪 [6] - 公司正在商业化先进细胞应用,推出了Mesh MEA有机体平台 [6] - 公司看好这些新兴业务的增长前景,预计未来几年可以实现10%以上的整体收入增长 [13][14] - 公司在一些细分领域如MEA和生物制造方面处于领先地位,有较强的定价能力和壁垒 [14][24] 管理层对经营环境和未来前景的评论 - 2024年公司整体收入预计持平或温和增长,上半年受中国市场疲软影响较大,下半年有望实现强劲增长 [9] - 公司预计2024年毛利率将达到60%左右,经调整EBITDA率将提升至中高teens [9] - 管理层对公司新产品的商业化前景持乐观态度,认为这些新产品将成为公司未来增长的重要驱动力 [4][5][6] - 管理层表示,公司正在寻求通过授权许可等方式来拓展一些新兴业务领域,同时也在关注潜在的小型并购机会 [23][24] 问答环节重要的提问和回答 问题1 **Paul Knight 提问** 新产品在2024年的增量贡献有多大 [11] **Jim Green 回答** 新产品中VivaMARS和生物制造电穿孔等领域有望实现较快增长,可能贡献2-5个百分点的增量 [11][14] 先进细胞应用如有机体测量系统也有很大增长潜力,可能贡献3-6个百分点的增量 [11] 整体来看,公司的基础业务有望保持5-7%的增长,新兴业务可能贡献另外4-5个百分点的增量 [14] 问题2 **Frank DiLorenzo 提问** 公司是否有在美国以外市场拓展的计划 [21][22] **Jim Green 回答** 公司主要以美国市场为基准设计产品,然后复制到中国和欧洲等其他主要市场 [22] 未来公司也会考虑通过授权许可等方式来拓展一些新兴业务领域,以及潜在的小型并购机会 [24][25]

Enabling discovery, safety and production of tomorrow’s therapeutics NASDAQ: HBIO Q4’23 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer Forward-Looking Statements and Non-GAAP Financial Information Forward-LookingStatements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “ ...